ImmunityBio (IBRX) Announces NCCN Update Clinical Practice Guidelines to Include ANKTIVA for Papillary-Only NMIBC

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best NASDAQ stocks under $30 to buy. On March 17, ImmunityBio announced that the ...
Seeking Alpha

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of ...
Nasdaq

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...
MarketWatch

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA(R) Plus CAR-NK, Chemo-Free Therapy

The MarketWatch News Department was not involved in the creation of this content. -- Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of ...
Nasdaq

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) ...
AOL

A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know

ImmunityBio, Inc. is a San Diego-based biotechnology company specializing in next-generation immunotherapies and vaccines for cancer and infectious diseases. The company develops immunotherapy and ...